Ann: Antimicrobial Platform Update and Launch of BTX 1801 Study, page-79

25 March 2020
Botanix announces top line BTX 1204 atopic dermatitis data
• BTX 1204 did not achieve statistical significance in the primary and secondary endpoints in its
Phase 2 atopic dermatitis study
• Botanix will be finalising a comprehensive review of the study data and will provide an update
on the BTX 1204 program and its broader dermatology platform
Philadelphia PA and Sydney Australia, 25 March 2020: Clinical stage synthetic cannabinoid company
Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) today announced that BTX
1204 did not meet the primary endpoint in its Phase 2 study evaluating the safety and efficacy in
patients with moderate atopic dermatitis (“1204 Study”).


Sad